Clinicopathologic Consequences Following Discontinuation of Rifaximin in Patients with Sickle Cell Disease

Authors

Seah H. Lim, New York Medical CollegeFollow
Dibyendu Dutta

DOI

10.1002/ajh.25798

Journal Title

American Journal of Hematology

First Page

151

Last Page

153

Document Type

Article

Publication Date

6-2020

Department

Medicine

Keywords

Adult, Anemia, Sickle Cell, Female, Humans, Male, Rifaximin

Disciplines

Medicine and Health Sciences

Recommended Citation

Lim, S. H., & Dutta, D. (2020). Clinicopathologic Consequences Following Discontinuation of Rifaximin in Patients with Sickle Cell Disease. American Journal of Hematology, 95 (6), 151-153. https://doi.org/10.1002/ajh.25798